The DOI matches its Crossref record; 339 of the 339 references it cites were found in a registry or an index.
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Open accessAbstract
Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (15%) (SCLC). The 5-year survival rate for NSCLC patients remains very low (about 16% at 5 years). The two predominant NSCLC histological phenotypes are adenocarcinoma (ADC) and squamous cell carcinoma (LSQCC). ADCs display several recurrent genetic alterations, including: KRAS, BRAF and EGFR mutations; recurrent mutations and amplifications of several oncogenes, including ERBB2, MET, FGFR1 and FGFR2; fusion oncogenes involving ALK, ROS1, Neuregulin1 (NRG1) and RET. In LSQCC recurrent mutations of TP53, FGFR1, FGFR2, FGFR3, DDR2 and genes of the PI3K pathway have been detected, quantitative gene abnormalities of PTEN and CDKN2A. Developments in the characterization of lung cancer molecular abnormalities provided a strong rationale for new therapeutic options and for understanding the mechanisms of drug resistance. However, the complexity of lung cancer genomes is particularly high, as shown by deep-sequencing studies supporting the heterogeneity of lung tumors at cellular level, with sub-clones exhibiting different combinations of mutations. Molecular studies performed on lung tumors during treatment have shown the phenomenon of clonal evolution, thus supporting the occurrence of a temporal tumor heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Evidence for Human Lung Stem Cells
Kajstura, J., Rota, M., Hall, S. R., Hosoda, T., D'Amario, D., Sanada, F., Zheng, H., Ogórek, B., Rondon-Clavo, C., Ferreira-Martins, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1101324 · Cited by 380
RetractedHMGA2 functions as a competing endogenous RNA to promote lung cancer progression
Kumar, M. S., Armenteros-Monterroso, E., East, P., Chakravorty, P., Matthews, N., Winslow, M. M., & Downward, J. (2014) · Nature · doi:10.1038/nature12785 · Cited by 253
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 2×
“Recently, a double-blind, phase III trial, randomly assigned 616 NSCLC patients with metastatic non-squamous NSCLC without EGFR and ALK mutations who were chemotherapy-naïve to receive pemetrexed and a platinum-based drug plus either placebo or pembrolizumab [284].”
BackgroundComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“8 months) and a trend towards an improved survival (after 18 months, 83% in the osimertinib arm, compared to 71% in standard EGF-TKIs arm) [330].”
ResultRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 10×
“Third generation EGFR TKIs, such as osimertinib, are selective inhibitors of both the original sensitizing and T790M mutations but spar the normal EGFR.”
BackgroundInfluentialFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · cited 8×
“Considerable variation in the extent of intra-tumor heterogeneity was observed among various tumors [90].”
BackgroundInfluentialComprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,195
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025 · cited 2×
“Taking into account the various studies on this topic [13,14], it was now proposed a molecular classification identifying the following subtypes: the terminal respiratory unit, also known as bronchioid; the proximal-inflammatory, also known as squamoid; the proximal proliferative, also known as magoid.”
BackgroundCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“All these three drugs have shown a significant anti-tumor activity in ROS1-mutated lung adenocarcinomas [343].”
BackgroundTravis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,905
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 5×
“On the other hand, frequent copy number alterations have been observed: gain of TERT (42%), MYC (31%), MCL1 (34%), EGFR (22%), ERBB2 (20%), NKX2-1 (18%); losses of TP53 (18%), CDKN2A (24%, 10% homozygous) [12].”
BackgroundInfluentialType 2 alveolar cells are stem cells in adult lung
Barkauskas, C. E., Cronce, M. J., Rackley, C. R., Bowie, E. J., Keene, D. R., Stripp, B. R., Randell, S. H., Noble, P. W., & Hogan, B. L. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68782 · Cited by 1,776
21st-Century Hazards of Smoking and Benefits of Cessation in the United States
Jha, P., Ramasundarahettige, C., Landsman, V., Rostron, B., Thun, M., Anderson, R. N., McAfee, T., & Peto, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211128 · Cited by 1,767 · cited 3×
“It was estimated for men and women comprised between 25 and 79 years of age that the rate of death from any cause among current smokers was about three times that among those who had never smoked; the increased mortality among smokers was mostly due to neoplastic, vascular respiratory diseases life expectancy was shor…”
BackgroundResultUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“A multiplexed assay of oncogenic drivers showed a mutation of these genes in 64% of lung adenocarcinomas [20].”
BackgroundIdentification and expansion of the tumorigenic lung cancer stem cell population
Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., & De Maria, R. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402283 · Cited by 1,707
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1×
“lack fo benefit from PD-1 blockade (7% overall response) in KRAS-mutant lung adenocarcinomas, a phenomenon that cannot be related to KRAS mutations in that KRAS-mutant lung adenocarcinomas without LKB1 mutations are responsive (about 35% of overall responses) to PD-1 blocking [354].”
BackgroundThe Eighth Edition Lung Cancer Stage Classification
Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017) · Chest · doi:10.1016/j.chest.2016.10.010 · Cited by 1,641
Raaschou-Nielsen, O., Andersen, Z. J., Beelen, R., Samoli, E., Stafoggia, M., Weinmayr, G., Hoffmann, B., Fischer, P., Nieuwenhuijsen, M. J., Brunekreef, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70279-1 · Cited by 1,582
Basal cells as stem cells of the mouse trachea and human airway epithelium
Rock, J. R., Onaitis, M. W., Rawlins, E. L., Lu, Y., Clark, C. P., Xue, Y., Randell, S. H., & Hogan, B. L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906850106 · Cited by 1,559
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · cited 2×
“These studies raised many interesting findings and underlined the need of carefully exploring at molecular level NSCLC patients undergoing treatment with immune checkpoint inhibitors [299].”
BackgroundNon–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · cited 1×
“The phase I/II Check Mate 032 trial showed a rate of objective response of 10% in patients treated with nivolumab alone and 19−33% of objective responses in patients treated with nivolumab and ipilimumab (at various doses) [318].”
Backgroundvan Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183 · cited 1×
“Both Afatinib and Dacomitinib showed an increased PFS compared to a first-generation EGFR TKI, such as gefitinib [21,326,327].”
Background50-Year Trends in Smoking-Related Mortality in the United States
Thun, M. J., Carter, B. D., Feskanich, D., Freedman, N. D., Prentice, R., Lopez, A. D., Hartge, P., & Gapstur, S. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211127 · Cited by 1,177
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 2×
“The main findings of this study were that: Tumor mutation burden (TMB) is significantly associated with improved efficacy of combination immunotherapy: TMB was higher in patients with objective response compared with those with no response; computational predicted neoantigen burden correlates with response; TMB is ind…”
BackgroundShaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091 · cited 1×
“Interestingly, secondary analysis of the phase I KEYNOTE-001 study found that patients who previously received radiotherapy for NSCLC had significantly longer PFS and OS with pembrolizumab treatment versus patients who did not receive radiotherapy [314].”
BackgroundRudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
A small-cell lung cancer genome with complex signatures of tobacco exposure
Pleasance, E. D., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A., Jones, D., Lin, M.-L., Beare, D., Lau, K. W., Greenman, C., et al. (2010) · Nature · doi:10.1038/nature08629 · Cited by 1,066
Alveolar progenitor and stem cells in lung development, renewal and cancer
Desai, T. J., Brownfield, D. G., & Krasnow, M. A. (2014) · Nature · doi:10.1038/nature12930 · Cited by 1,060
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973 · cited 1×
“A recent study investigated whether the patients’ sex influences cancer immunotherapy efficacy, showing that both for NSCLC patients and melanoma patients the relative reduction of the risk of death that is achievable with immune check inhibitors, compared with standard therapies is significantly higher in male patien…”
BackgroundIntratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer Cells
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3557 · Cited by 947
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., Kim, S. Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009) · Nature Genetics · doi:10.1038/ng.465 · Cited by 942
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863 · cited 1×
“KRAS and EGFR mutations are usually present in the founder clones of lung adenocarcinoma, while TP53 mutations are frequently acquired during advanced stages of tumor development, thus suggesting a role during tumor progression [324].”
BackgroundHorn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
Rawlins, E. L., Okubo, T., Xue, Y., Brass, D. M., Auten, R. L., Hasegawa, H., Wang, F., & Hogan, B. L. M. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.04.002 · Cited by 853
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Hou, J.-M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., Priest, L. J. C., Greystoke, A., Zhou, C., Morris, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3716 · Cited by 842
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer
Jiang, F., Qiu, Q., Khanna, A., Todd, N. W., Deepak, J., Xing, L., Wang, H., Liu, Z., Su, Y., Stass, S. A., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0393 · Cited by 788
Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., Pratesi, G., Fabbri, A., Andriani, F., Tinelli, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905653106 · Cited by 767
Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells
Nabhan, A. N., Brownfield, D. G., Harbury, P. B., Krasnow, M. A., & Desai, T. J. (2018) · Science · doi:10.1126/science.aam6603 · Cited by 755
Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 738
Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor
Zacharias, W. J., Frank, D. B., Zepp, J. A., Morley, M. P., Alkhaleel, F. A., Kong, J., Zhou, S., Cantu, E., & Morrisey, E. E. (2018) · Nature · doi:10.1038/nature25786 · Cited by 737
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694
Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury
Vaughan, A. E., Brumwell, A. N., Xi, Y., Gotts, J. E., Brownfield, D. G., Treutlein, B., Tan, K., Tan, V., Liu, F. C., Looney, M. R., et al. (2015) · Nature · doi:10.1038/nature14112 · Cited by 677
Zhang, W. C., Shyh-Chang, N., Yang, H., Rai, A., Umashankar, S., Ma, S., Soh, B. S., Sun, L. L., Tai, B. C., Nga, M. E., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.050 · Cited by 660
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · cited 3×
“Importantly, KEAP1/KRAS-mutant lung adenocarcinomas are dependent upon increased glutaminolysis and are therapeutically sensitive to pharmacologic inhibition of glutaminase [249].”
BackgroundInfluentialHellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645
Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643 · cited 1×
“Among these models, the most relevant was the model of the double knockout for both TP53 and RB1 in the lung epithelium of adult mice [265].”
BackgroundHanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Lung development: orchestrating the generation and regeneration of a complex organ
Herriges, M., & Morrisey, E. E. (2014) · Development · doi:10.1242/dev.098186 · Cited by 613
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
Travis, W. D., Brambilla, E., & Riely, G. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9270 · Cited by 599
Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598
Mollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.005 · Cited by 588
Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2229 · Cited by 588
Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568
Zepp, J. A., Zacharias, W. J., Frank, D. B., Cavanaugh, C. A., Zhou, S., Morley, M. P., & Morrisey, E. E. (2017) · Cell · doi:10.1016/j.cell.2017.07.034 · Cited by 567
Rudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 547
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537 · cited 3×
“Given this important contribution of MYC to KRAS-driven lung tumorigenesis, it is not surprising that a pharmacological treatment based on combining DNA demethylating agents (azacytidine) and histone deacetylase inhibitors, able to inhibit MYC signaling, reduces MYC-driven cell proliferation, associated with an enhanc…”
BackgroundSutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · cited 3×
“According to these observations it was concluded that neuroendocrine cells contribute to SCLCs, while Clara cells do not seem to be involved in SCLC formation [266].”
BackgroundMethodp63+Krt5+ distal airway stem cells are essential for lung regeneration
Zuo, W., Zhang, T., Wu, D. Z., Guan, S. P., Liew, A.-A., Yamamoto, Y., Wang, X., Lim, S. J., Vincent, M., Lessard, M., et al. (2015) · Nature · doi:10.1038/nature13903 · Cited by 529
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.006 · Cited by 526
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw611 · Cited by 524
Ott, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 517
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Borromeo, M. D., Savage, T. K., Kollipara, R. K., He, M., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 503
Rekhtman, N., Pietanza, M. C., Hellmann, M. D., Naidoo, J., Arora, A., Won, H., Halpenny, D. F., Wang, H., Tian, S. K., Litvak, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2946 · Cited by 487
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Lim, J. S., Ibaseta, A., Fischer, M. M., Cancilla, B., O’Young, G., Cristea, S., Luca, V. C., Yang, D., Jahchan, N. S., Hamard, C., et al. (2017) · Nature · doi:10.1038/nature22323 · Cited by 485
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Hammerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., Brace, L. E., Woods, B. A., Lin, W., Zhang, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0005 · Cited by 482
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478 · cited 3×
“To evaluate the oncogenic potential of EGFR mutations, transgenic mice expressing either EGFR∆L747-S752 or EGFRL858R in type II pneumocytes have been developed [233].”
BackgroundInfluentialNon-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties
Leung, E. L.-H., Fiscus, R. R., Tung, J. W., Tin, V. P.-C., Cheng, L. C., Sihoe, A. D.-L., Fink, L. M., Ma, Y., & Wong, M. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014062 · Cited by 473
Daniel, V. C., Marchionni, L., Hierman, J. S., Rhodes, J. T., Devereux, W. L., Rudin, C. M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4210 · Cited by 467
Notch-Dependent Differentiation of Adult Airway Basal Stem Cells
Rock, J. R., Gao, X., Xue, Y., Randell, S. H., Kong, Y.-Y., & Hogan, B. L. M. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.04.003 · Cited by 465
Vokes, E. E., Ready, N., Felip, E., Horn, L., Burgio, M. A., Antonia, S. J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy041 · Cited by 464
Nogova, L., Sequist, L. V., Perez Garcia, J. M., Andre, F., Delord, J.-P., Hidalgo, M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schuler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 432
Sullivan, J. P., Spinola, M., Dodge, M., Raso, M. G., Behrens, C., Gao, B., Schuster, K., Shao, C., Larsen, J. E., Sullivan, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0881 · Cited by 416
Deng, S., Yang, X., Lassus, H., Liang, S., Kaur, S., Ye, Q., Li, C., Wang, L.-P., Roby, K. F., Orsulic, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010277 · Cited by 415
Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30148-7 · Cited by 412
Solomon, B. J., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Tang, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.4794 · Cited by 409
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E., & Lokshin, A. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003077 · Cited by 407
Peters, S., Gettinger, S., Johnson, M. L., Jänne, P. A., Garassino, M. C., Christoph, D., Toh, C. K., Rizvi, N. A., Chaft, J. E., Carcereny Costa, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 400
Büttner, R., Gosney, J. R., Skov, B. G., Adam, J., Motoi, N., Bloom, K. J., Dietel, M., Longshore, J. W., López-Ríos, F., Penault-Llorca, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7642 · Cited by 397
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
Incidence and mortality of lung cancer: global trends and association with socioeconomic status
Wong, M. C. S., Lao, X. Q., Ho, K.-F., Goggins, W. B., & Tse, S. L. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14513-7 · Cited by 381
Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03099-x · Cited by 377
Dovedi, S. J., Cheadle, E. J., Popple, A. L., Poon, E., Morrow, M., Stewart, R., Yusko, E. C., Sanders, C. M., Vignali, M., Emerson, R. O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1673 · Cited by 370
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
Dutt, A., Ramos, A. H., Hammerman, P. S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K. E., Stransky, N., Greulich, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020351 · Cited by 369
Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
Denny, S. K., Yang, D., Chuang, C.-H., Brady, J. J., Lim, J. S., Grüner, B. M., Chiou, S.-H., Schep, A. N., Baral, J., Hamard, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.052 · Cited by 368
Govindan, R., Szczesna, A., Ahn, M.-J., Schneider, C.-P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7629 · Cited by 365
Rekhtman, N., Paik, P. K., Arcila, M. E., Tafe, L. J., Oxnard, G. R., Moreira, A. L., Travis, W. D., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2109 · Cited by 364
Anatomically and Functionally Distinct Lung Mesenchymal Populations Marked by Lgr5 and Lgr6
Lee, J.-H., Tammela, T., Hofree, M., Choi, J., Marjanovic, N. D., Han, S., Canner, D., Wu, K., Paschini, M., Bhang, D. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.028 · Cited by 361
Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.004 · Cited by 346
Telomere dysfunction causes alveolar stem cell failure
Alder, J. K., Barkauskas, C. E., Limjunyawong, N., Stanley, S. E., Kembou, F., Tuder, R. M., Hogan, B. L. M., Mitzner, W., & Armanios, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504780112 · Cited by 339 · cited 2×
“In fact, in mice short telomeres result in a defective function of type 2 alveolar epithelial cells, due to their premature senescence and to the induction of a reactive inflammatory response [150].”
BackgroundSun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 335
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T. M., Delrosario, R., Jen, K.-Y., Gurley, K. E., Kemp, C. J., et al. (2015) · Nature · doi:10.1038/nature13898 · Cited by 330
Wu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 319
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., Zander, T., Leenders, F., George, J., Müller, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4518 · Cited by 317
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C., & Martins, C. P. (2016) · Nature · doi:10.1038/nature16967 · Cited by 313
Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinoma
Xu, X., Rock, J. R., Lu, Y., Futtner, C., Schwab, B., Guinney, J., Hogan, B. L. M., & Onaitis, M. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112499109 · Cited by 303
Gong, X., Li, X., Jiang, T., Xie, H., Zhu, Z., Zhou, F., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.014 · Cited by 303
Justilien, V., Walsh, M. P., Ali, S. A., Thompson, E. A., Murray, N. R., & Fields, A. P. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.008 · Cited by 293
Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
McFadden, D. G., Papagiannakopoulos, T., Taylor-Weiner, A., Stewart, C., Carter, S. L., Cibulskis, K., Bhutkar, A., McKenna, A., Dooley, A., Vernon, A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.031 · Cited by 288
Paul, M. K., Bisht, B., Darmawan, D. O., Chiou, R., Ha, V. L., Wallace, W. D., Chon, A. T., Hegab, A. E., Grogan, T., Elashoff, D. A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.009 · Cited by 286
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
Augustyn, A., Borromeo, M., Wang, T., Fujimoto, J., Shao, C., Dospoy, P. D., Lee, V., Tan, C., Sullivan, J. P., Larsen, J. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410419111 · Cited by 282
Wilkerson, M. D., Yin, X., Hoadley, K. A., Liu, Y., Hayward, M. C., Cabanski, C. R., Muldrew, K., Miller, C. R., Randell, S. H., Socinski, M. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0199 · Cited by 278
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233739 · Cited by 269
Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma
Sutherland, K. D., Song, J.-Y., Kwon, M. C., Proost, N., Zevenhoven, J., & Berns, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319963111 · Cited by 266
The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.059 · Cited by 265
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K.-K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255
Sacher, A. G., Dahlberg, S. E., Heng, J., Mach, S., Jänne, P. A., & Oxnard, G. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4482 · Cited by 254
Singh, S., Trevino, J., Bora-Singhal, N., Coppola, D., Haura, E., Altiok, S., & Chellappan, S. P. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-73 · Cited by 250
Yuan, X., Wu, H., Han, N., Xu, H., Chu, Q., Yu, S., Chen, Y., & Wu, K. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0087-z · Cited by 248
A crucial requirement for Hedgehog signaling in small cell lung cancer
Park, K.-S., Martelotto, L. G., Peifer, M., Sos, M. L., Karnezis, A. N., Mahjoub, M. R., Bernard, K., Conklin, J. F., Szczepny, A., Yuan, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2473 · Cited by 247
Selective activation of p53-mediated tumour suppression in high-grade tumours
Junttila, M. R., Karnezis, A. N., Garcia, D., Madriles, F., Kortlever, R. M., Rostker, F., Brown Swigart, L., Pham, D. M., Seo, Y., Evan, G. I., et al. (2010) · Nature · doi:10.1038/nature09526 · Cited by 245
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
Ferone, G., Song, J.-Y., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J.-P., Proost, N., Gargiulo, G., & Berns, A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.001 · Cited by 244
Jones, M. H., Virtanen, C., Honjoh, D., Miyoshi, T., Satoh, Y., Okumura, S., Nakagawa, K., Nomura, H., & Ishikawa, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15693-6 · Cited by 241
Hui, R., Garon, E. B., Goldman, J. W., Leighl, N. B., Hellmann, M. D., Patnaik, A., Gandhi, L., Eder, J. P., Ahn, M.-J., Horn, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx008 · Cited by 237
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Simbolo, M., Mafficini, A., Sikora, K. O., Fassan, M., Barbi, S., Corbo, V., Mastracci, L., Rusev, B., Grillo, F., Vicentini, C., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4853 · Cited by 233
Derks, J. L., Leblay, N., Thunnissen, E., van Suylen, R. J., den Bakker, M., Groen, H. J. M., Smit, E. F., Damhuis, R., van den Broek, E. C., Charbrier, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1921 · Cited by 232
Gwinn, D. M., Lee, A. G., Briones-Martin-del-Campo, M., Conn, C. S., Simpson, D. R., Scott, A. I., Le, A., Cowan, T. M., Ruggero, D., & Sweet-Cordero, E. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.003 · Cited by 230
Patel, M., Lu, L., Zander, D. S., Sreerama, L., Coco, D., & Moreb, J. S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.033 · Cited by 220
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C., Brodie, S. A., Palleschi, A., Alloisio, M., Pariscenti, G., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002162 · Cited by 212
Liu, Y.-P., Yang, C.-J., Huang, M.-S., Yeh, C.-T., Wu, A. T. H., Lee, Y.-C., Lai, T.-C., Lee, C.-H., Hsiao, Y.-W., Lu, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1733 · Cited by 210
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Drapkin, B. J., George, J., Christensen, C. L., Mino-Kenudson, M., Dries, R., Sundaresan, T., Phat, S., Myers, D. T., Zhong, J., Igo, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0935 · Cited by 210
Sarvi, S., Mackinnon, A. C., Avlonitis, N., Bradley, M., Rintoul, R. C., Rassl, D. M., Wang, W., Forbes, S. J., Gregory, C. D., & Sethi, T. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1541 · Cited by 208
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Kim, Y., Hammerman, P. S., Kim, J., Yoon, J.-A., Lee, Y., Sun, J.-M., Wilkerson, M. D., Pedamallu, C. S., Cibulskis, K., Yoo, Y. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8556 · Cited by 202
Jung, M.-J., Rho, J.-K., Kim, Y.-M., Jung, J. E., Jin, Y. B., Ko, Y.-G., Lee, J.-S., Lee, S.-J., Lee, J. C., & Park, M.-J. (2013) · Oncogene · doi:10.1038/onc.2012.37 · Cited by 201
Hassan, K. A., Wang, L., Korkaya, H., Chen, G., Maillard, I., Beer, D. G., Kalemkerian, G. P., & Wicha, M. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0370 · Cited by 199
Wilbertz, T., Wagner, P., Petersen, K., Stiedl, A.-C., Scheble, V. J., Maier, S., Reischl, M., Mikut, R., Altorki, N. K., Moch, H., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.49 · Cited by 197
Dardaei, L., Wang, H. Q., Singh, M., Fordjour, P., Shaw, K. X., Yoda, S., Kerr, G., Yu, K., Liang, J., Cao, Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4497 · Cited by 197
Telomerase mutations in smokers with severe emphysema
Stanley, S. E., Chen, J. J. L., Podlevsky, J. D., Alder, J. K., Hansel, N. N., Mathias, R. A., Qi, X., Rafaels, N. M., Wise, R. A., Silverman, E. K., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78554 · Cited by 196 · cited 1×
“In fact, recent studies have shown that mutations in telomerase (TERT and TR) represent the most commonly observed risk factor predisposing to the development of idiopathic pulmonary fibrosis; furthermore, telomerase mutations predispose to emphysema development in smoker patients, as well as alpha-1 antitrypsin defic…”
BackgroundGenomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Miyoshi, T., Umemura, S., Matsumura, Y., Mimaki, S., Tada, S., Makinoshima, H., Ishii, G., Udagawa, H., Matsumoto, S., Yoh, K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0355 · Cited by 195
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194
Sen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., Redwood, A. B., Fan, Y. H., Li, L., Glisson, B. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3409 · Cited by 194
Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L., Zahnow, C. A., Gabrielson, E., Velculescu, V. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.006 · Cited by 191
Yang, Y., Riccio, P., Schotsaert, M., Mori, M., Lu, J., Lee, D.-K., García-Sastre, A., Xu, J., & Cardoso, W. V. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.03.001 · Cited by 191
Tokito, T., Azuma, K., Kawahara, A., Ishii, H., Yamada, K., Matsuo, N., Kinoshita, T., Mizukami, N., Ono, H., Kage, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.020 · Cited by 188
Jiang, T., Collins, B. J., Jin, N., Watkins, D. N., Brock, M. V., Matsui, W., Nelkin, B. D., & Ball, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2762 · Cited by 186
Kim, S., Kim, M.-Y., Koh, J., Go, H., Lee, D. S., Jeon, Y. K., & Chung, D. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.013 · Cited by 184
Swarts, D. R. A., Ramaekers, F. C. S., & Speel, E.-J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.05.001 · Cited by 179
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Sos, M. L., Dietlein, F., Peifer, M., Schöttle, J., Balke-Want, H., Müller, C., Koker, M., Richters, A., Heynck, S., Malchers, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207310109 · Cited by 179
Mok, T. S. K., Kim, S.-W., Wu, Y.-L., Nakagawa, K., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9250 · Cited by 179
Gainor, J. F., Tan, D. S. W., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., de Marinis, F., Spitaleri, G., Schultz, K., Friboulet, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3009 · Cited by 177
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion
Dovey, J. S., Zacharek, S. J., Kim, C. F., & Lees, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803574105 · Cited by 177
John, T., Kohler, D., Pintilie, M., Yanagawa, N., Pham, N.-A., Li, M., Panchal, D., Hui, F., Meng, F., Shepherd, F. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2224 · Cited by 176
Nuclear factor I/B is an oncogene in small cell lung cancer
Dooley, A. L., Winslow, M. M., Chiang, D. Y., Banerji, S., Stransky, N., Dayton, T. L., Snyder, E. L., Senna, S., Whittaker, C. A., Bronson, R. T., et al. (2011) · Genes & Development · doi:10.1101/gad.2046711 · Cited by 174
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth
Morita, M., Sato, T., Nomura, M., Sakamoto, Y., Inoue, Y., Tanaka, R., Ito, S., Kurosawa, K., Yamaguchi, K., Sugiura, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.004 · Cited by 171
Lung Cancer and Lung Stem Cells: Strange Bedfellows?
Giangreco, A., Groot, K. R., & Janes, S. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-984pp · Cited by 169
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3950 · Cited by 167
Romero, O. A., Torres-Diz, M., Pros, E., Savola, S., Gomez, A., Moran, S., Saez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 165
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 165
Pacheco-Pinedo, E. C., Durham, A. C., Stewart, K. M., Goss, A. M., Lu, M. M., DeMayo, F. J., & Morrisey, E. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44871 · Cited by 164 · cited 5×
“KRAS mutations leads to a more aggressive form of lung cancer with an embryonic progenitor phenotype [229].”
BackgroundInfluentialIdentification of cancer initiating cells in K-Ras driven lung adenocarcinoma
Mainardi, S., Mijimolle, N., Francoz, S., Vicente-Dueñas, C., Sánchez-García, I., & Barbacid, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320383110 · Cited by 164
Zheng, Y., de la Cruz, C. C., Sayles, L. C., Alleyne-Chin, C., Vaka, D., Knaak, T. D., Bigos, M., Xu, Y., Hoang, C. D., Shrager, J. B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.021 · Cited by 164
Salnikov, A. V., Gladkich, J., Moldenhauer, G., Volm, M., Mattern, J., & Herr, I. (2010) · International Journal of Cancer · doi:10.1002/ijc.24822 · Cited by 163
Fgf10 -positive cells represent a progenitor cell population during lung development and postnatally
Agha, E. E., Herold, S., Alam, D. A., Quantius, J., MacKenzie, B., Carraro, G., Moiseenko, A., Chao, C., Minoo, P., Seeger, W., et al. (2013) · Development · doi:10.1242/dev.099747 · Cited by 161
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
He, J., Huang, Z., Han, L., Gong, Y., & Xie, C. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5270 · Cited by 314
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng, Y. Y., Rath, E. M., Linton, A., Yuen, M. L., Takahashi, K., & Lee, K. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s186843 · Cited by 31
Metadata
- Authors
- Testa, U., Castelli, G., & Pelosi, E.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-07-27
- Volume
- 10
- Issue
- 8
- Pages
- 248
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2884192683
- Cited by
- 403
- References
- 339
- FWCI
- 28.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.